CytoDyn reminds shareholders to register 24 hours before the Annual General Meeting on November 24th

The management team will present the future strategy of the company

VANCOUVER, Wash., Nov. 16, 2021 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today urged shareholders to register 24 hours prior to meeting time to attend that meeting. As previously announced, the upcoming 2021 Annual General Meeting has been postponed to November 24, 2021 (the “Annual Meeting”) at 8:00 am Pacific Time.

The Annual General Meeting can be accessed virtually by registering at:

www.cesonlineservices.com/cydy21_vm

After registering, shareholders will receive a confirmation email with a link and instructions for accessing the virtual general meeting. Requests to remotely register to attend the AGM must be received no later than November 23, 2021, 8:00 a.m. Pacific Time.

At the annual meeting, the CytoDyn management team (Drs. Nader Pourhassan, Scott Kelly, Christopher Recknor as well as Nitya Ray and Mr. Antonio Migliarese) will present the company’s vision for next year.

Shareholders can vote by completing, signing and dating the BLUE proxy card and sending it in immediately in the stamped return envelope provided with the final proxy declaration, or by following the instructions on their proxy card to vote online or by telephone. Returning a power of attorney card does not prevent shareholders from voting at the Annual General Meeting, but it does ensure that their vote is counted if they are unable to attend.

The record date for the postponed Annual General Meeting continues to be the close of business on September 1, 2021. Shareholders who have already voted do not have to cast their votes again unless they wish to change their vote. Powers of attorney previously given will be voted on in the newly convened meeting if they are not properly revoked. Shareholders who have not yet voted or who would like to change their votes are requested to do so immediately using the instructions in their instruction form or the proxy card.

The story goes on

Please note that the nominations for the election of directors and the compensation of our named officers under NYSE rules are non-discretionary proposals. If you are a beneficial owner and you do not give voting instructions to your broker who holds stocks for you, your stocks will not be put to the vote on these proposals. In contrast, the amendment to the deed of incorporation and the advisory vote on the appointment of auditors are discretionary proposals. Accordingly, if you do not give voting instructions to your broker holding shares for you, your broker will vote on your shares as recommended by the Board of Directors on this proposal.

If you have any questions or need assistance with voting on your shares, please contact our proxy:

Morrow Sodali LLC
Toll-free shareholder call: (800) 662-5200
Banks, Brokers, Trustees, and Other Nominees Call Collect: (203) 658-9400
Email: [email protected]

Alliance advisor
Call Toll Free: (833) 814-9456
Email: [email protected]

About CytoDyn

CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications using Leronlimab, a novel humanized monoclonal antibody that targets the CCR5 receptor. CCR5 plays a critical role in HIV’s ability to invade and infect healthy T cells, and appears to be implicated in tumor metastasis and immune-mediated diseases such as NASH.

CytoDyn successfully completed a pivotal Phase 3 study of leronlimab in combination with standard antiretroviral therapies in HIV-infected patients who were highly experienced with limited treatment options. CytoDyn is working hard to re-submit its BLA for this HIV combination therapy since CytoDyn received a BLA filing refusal in July 2020, which is expected to be completed in the first quarter of calendar year 2022. CytoDyn has also completed a phase 2b / 3 study of leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-oriented study for the indication leronlimab monotherapy. If successful, it could support approval to extend the label. Clinical results to date from two studies have shown that leronlimab can maintain suppressed viral loads in a subpopulation of R5 HIV patients who have chosen to switch from their daily pill regimen to a once-weekly subcutaneous dose of leronlimab. Several patients in the Phase 2b extension arm of leronlimab remained virally suppressed for nearly 7 years, and many patients in our Phase 2b / 3 study were on monotherapy for two and four years with suppressed viral load.

CytoDyn recently completed a phase 2 clinical study with leronlimab in mTNBC and a phase 2 basket study in solid tumor cancers (22 different cancer indications). A phase 2 study of post-acute effects of SARS COV-2, also known as COVID-19 long-haul flights, and a phase 2 clinical study for NASH are ongoing. CytoDyn has already completed a phase 2 and phase 3 study for mild to moderate or severe to severe COVID-19 patients in whom CytoDyn did not meet its primary or secondary endpoints, with the exception of the secondary endpoint in the critical one Study sick subpopulation. More information is available at www.cytodyn.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and phrases that reflect optimism, satisfaction or disappointment about current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projected,” “planet”, “anticipates” and Variations or the use of future tenses identify forward-looking statements, but the lack of them does not mean that any statement is not forward-looking. Forward-looking statements include, in particular, statements about Leronlimab, its ability to achieve positive health outcomes, the possible outcomes of clinical trials, studies or other programs or the ability to continue such programs, the ability to obtain regulatory approvals for commercial sales, and the marketplace for actual commercial sale. The company’s forward-looking statements are not guarantees of performance, and actual results may vary due to risks and uncertainties including: (i) governmental requirements regarding the effectiveness of Leronlimab in the treatment of human immunodeficiency virus (“HIV”) patients with multiple resistance to current Standard of Care, COVID-19 Patients, and Metastatic Triple Negative Breast Cancer (“mTNBC”), including from the US Food and Drug Administration and various drug regulatory agencies in other countries; (ii) the company’s ability to raise additional capital to fund its business; (iii) the company’s ability to meet its liabilities; (iv) the Company’s ability to enter into partnership or license agreements with third parties; (v) the Company’s ability to timely identify patients for participation in its clinical trials; (vi) the company’s ability to obtain approval for a marketable product; (vii) the design, conduct and conduct of the Company’s clinical studies; (viii) the results of the Company’s clinical trials, including the possibility of adverse clinical trial results; (ix) the market for and marketability of each approved product; (x) the existence or development of any vaccine, drug, or other treatment that is considered by a medical practitioner or patient to be superior to the Company’s products; (xi) regulatory initiatives, regulatory compliance and regulatory approval process; (xii) legal proceedings, investigations or inquiries relating to the company or its products; (xiii) general terms and conditions; (xiv) changes in foreign, political and social conditions; (xv) actions or proposals by shareholders in relation to the company, its management or its board of directors; and (xvi) various other matters, many of which are beyond the control of the company. The company urges investors to specifically consider the various risk factors identified in its latest Form 10-K, as well as any risk factors or warnings contained in any subsequent Form 10-Q or Form 8-K submitted to the has been filed with the Securities and Exchange Commission. Except as required by law, the company assumes no responsibility to update forward-looking statements to reflect events or circumstances that occur after the date of this press release.

Important information

CytoDyn has filed a final proxy statement and the associated BLUE proxy card with the SEC in connection with obtaining proxies for the company’s 2021 annual meeting. Details on the nominees of the company’s Board of Directors for election at the 2021 annual meeting are contained in the declaration of proxy. BEFORE TAKING A VOTING DECISION, INVESTORS AND SHAREHOLDERS OF THE COMPANY ARE URGENT TO READ ALL RELEVANT DOCUMENTS ADDED TO THE SEC OR SUBMITTED TO THE SEC, INCLUDING THE END OF AGREEMENTS. Investors and shareholders can obtain a copy of the final proxy statement and other documents filed by the Company free of charge from the SEC’s website, www.sec.gov. Company shareholders can also obtain a copy of the final proxy and other relevant filing at no charge by mailing a request to CytoDyn Inc., 1111 Main Street, Suite 660, Vancouver, Washington 98660.

CONTACTS

Investors:
Cristina De Leon placeholder image
Office: 360.980.8524
[email protected]

OR

Mike Verrechia / Bill Dooley, 800-662-5200
Morning sodali
[email protected]

OR

Melissa Carlson, 833-814-9456
Alliance advisor
[email protected]

Media:
Dan Zacchei / Joe Germani
Sloane & Company
[email protected] / [email protected]

Comments are closed.